Entera Bio Ltd. ENTX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Entera Bio Ltd. (ENTX) is a healthcare company listed in the US with a market value of about $542M. In fiscal year 2025 it had revenue of $42000 and net income of -$11M, a net margin of -27235.7%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -35% a year, a 5-year average ROIC of -76%.
About Entera Bio
Entera Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $500000 in 2018 to $42000 in 2025, a decline of about 29.8% a year. It was profitable in 0 of the last 10 years in our data. It spends 14295% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42000 | $181000 | $0 | $134000 | $571000 | $365000 | $236000 | $500000 | — | — |
| Net income | -$11M | -$10M | -$9M | -$13M | -$12M | -$11M | -$11M | -$10M | -$11M | -$1M |
| Free cash flow | -$7M | -$7M | -$7M | -$13M | -$9M | -$11M | -$9M | -$10M | -$5M | -$3M |
| EPS (diluted) | $-0.07 | $-0.05 | $-0.05 | $-0.08 | $-0.07 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.01 |
| Net margin | -27235.7% | -5271.3% | — | -9754.5% | -2134.3% | -3072.9% | -4574.2% | -2060.8% | — | — |
| ROIC | -84.8% | -90.7% | -65.2% | -86.8% | -53.2% | -111.1% | -65.7% | -84.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $9.75, 214% above the current price; targets range from $9.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Entera Bio pay a dividend?
Not currently.
Is Entera Bio a good stock to buy?
We do not give buy or sell advice. Entera Bio scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.